Back to the main directory
Company Analysis / Equity
- National Storage REIT's Acquisition Strategy Bolsters Near-Term Growth by Morningstar
- Julius Baer Gives Four-Month Update; Previous Hiring Efforts Drive Net New Money Generation by Morningstar
- Immuno-Oncology Drugs Post Strong Data at ASCO, Supporting Our 2021 $28 Billion Sales Estimate by Morningstar
- Immuno-Oncology Drugs Post Strong Data at ASCO, Supporting Our 2021 $28 Billion Sales Estimate by Morningstar
- Immuno-Oncology Drugs Post Strong Data at ASCO, Supporting Our 2021 $28 Billion Sales Estimate by Morningstar
- Continued weakness in the natural gas business serves as a drag on the company. by Morningstar
- A strong quarter in the US by Edison Investment Research
- OPEC Extends Output Cuts by Nine Months, but Market Reckoning Still Coming in 2018 by Morningstar
- Lowering Canadian Natural Resources' Fair Value Estimate on Lower-Than-Expected Cost Reductions by Morningstar
- Lowering Canadian Natural Resources' Fair Value Estimate on Lower-Than-Expected Cost Reductions by Morningstar
- OPEC Extends Output Cuts by Nine Months, but Market Reckoning Still Coming in 2018 by Morningstar
- OPEC Extends Output Cuts by Nine Months, but Market Reckoning Still Coming in 2018 by Morningstar
- OPEC Extends Output Cuts by Nine Months, but Market Reckoning Still Coming in 2018 by Morningstar
- OPEC Extends Output Cuts by Nine Months, but Market Reckoning Still Coming in 2018 by Morningstar
- Roche's oncology and diagnostics dominance underlies its wide moat rating. by Morningstar
- Perjeta's Lower Market Potential Hits Our Roche FVE, but Shares Remain Compelling Value by Morningstar
- Adding Iamgold’s Cote Gold Project to Model After Prefeasibility Study and Partner Announcement by Morningstar
- You Can Benefit from GH Capital’s Online Payments Growth by Focus Equity
- Winnebago Has a Good 2Q Thanks to Grand Design Acquisition by Morningstar
- Lumentum Fared Well Despite Soft Demand in China and Got 3D Sensing Orders; Shares Fairly Valued by Morningstar
- Relaunching coverage of narrow-moat HD Supply with $43 per share fair value estimate. by Morningstar
- Relaunching Coverage of AT&T With Narrow Economic Moat, Negative Moat Trend, and FVE of $40 by Morningstar
- Relaunching Coverage of T-Mobile with No Economic Moat, Positive Moat Trend, and FVE of $67 by Morningstar
- Barbarians at Vocus' Gate by Morningstar
- ISL: Recovery of pricing power to be gradual; Neutral by Intermarket Securities Limited
- Julius Baer Gives Four-Month Update; Previous Hiring Efforts Drive Net New Money Generation by Morningstar
- Immuno-Oncology Drugs Post Strong Data at ASCO, Supporting Our 2021 $28 Billion Sales Estimate by Morningstar
- Immuno-Oncology Drugs Post Strong Data at ASCO, Supporting Our 2021 $28 Billion Sales Estimate by Morningstar
- Immuno-Oncology Drugs Post Strong Data at ASCO, Supporting Our 2021 $28 Billion Sales Estimate by Morningstar
- Immuno-Oncology Drugs Post Strong Data at ASCO, Supporting Our 2021 $28 Billion Sales Estimate by Morningstar
- Strong results; US remains the growth engine by AlphaValue
- Perrigo's Leadership Turnover Continues With Announced Departure of CEO by Morningstar
- OPEC Extends Output Cuts by Nine Months, but Market Reckoning Still Coming in 2018 by Morningstar
- OPEC Extends Output Cuts by Nine Months, but Market Reckoning Still Coming in 2018 by Morningstar
- OPEC Extends Output Cuts by Nine Months, but Market Reckoning Still Coming in 2018 by Morningstar
- OPEC Extends Output Cuts by Nine Months, but Market Reckoning Still Coming in 2018 by Morningstar
- OPEC Extends Output Cuts by Nine Months, but Market Reckoning Still Coming in 2018 by Morningstar
- OPEC Extends Output Cuts by Nine Months, but Market Reckoning Still Coming in 2018 by Morningstar
- We Are Placing HD Supply Under Review After the Company Announced the Sale of Its Waterworks Segment by Morningstar
- Roche's oncology and diagnostics dominance underlies its wide moat rating. by Morningstar
- Antidumping Tariffs Will Dent Lumber Firms' Near-Term Results, but Long-Term Outlook Intact by Morningstar
- Adding Iamgold’s Cote Gold Project to Model After Prefeasibility Study and Partner Announcement by Morningstar
- We expect CEO Sikka to reinvigorate Infosys' morale and strategic direction. by Morningstar
- Tesla's 1Q Likely a Preview of Its 2Q as Model 3 Launch Nears by Morningstar
- TripAdvisor Faces a Decelerating, Transitory 2Q; Long-Term Network Advantage Intact by Morningstar
- AT&T pursues acquisitions in a world where capacity, networks, and entertainment are converging. by Morningstar
- Relaunching Coverage of Verizon With a Narrow Economic Moat, Stable Moat Trend, and FVE of $48 by Morningstar
- Relaunching Coverage of Sprint With No Economic Moat, Stable Moat Trend, and FVE of $5 by Morningstar
- Macy’s Outlines a Path to Return to Growth but We Think It Is Still an Uphill Battle by Morningstar
- Evolis. Initiation de couverture by MidCap Partners